Business Wire

HANSHOW

8.11.2021 07:27:11 CET | Business Wire | Press release

Share
Hanshow Announces New AI Camera-Driven Solutions in China Developed in Collaboration With Microsoft and Sony Semiconductor Solutions

At the 2021 China International Import Expo (CIIE), Hanshow has announced a commercial AI camera-driven retail solution, developed through a collaboration with Microsoft and Sony Semiconductor Solutions Corporation (Sony). This solution combines Sony’s intelligent vision sensor IMX500, the world’s first image sensor equipped with AI functionality, with Microsoft Azure and its AI capabilities to achieve AI processing on edge. As part of the Partner Enablement Program through Microsoft AI & IoT Insider Labs, Microsoft Global ISV Hanshow continues to upgrade its intelligent solution to better serve its global customers especially in the retail industry.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211107005144/en/

In a busy retail setting, staff are often unable to complete timely and accurate monitoring of product shelf status. This results in products being out-of-stock, improperly arranged, lost sales, unsatisfied customers, and unattractive store appearance. Meanwhile, customer flow analysis is crucial for retailers to better understand customer behavior in their stores including traffic, visited areas, customer paths, dwell time and loyalty.

Hanshow’s AI retail solution monitors out-of-stock occurrences along with product volume status, customer traffic flows, sales levels, and other store information. This not only allows for real time out-of-stock notifications, but also stores and analyzes data over time to help managers optimize operations and displays.

This upgraded AI retail solution involves Hanshow’s AI calculations (product recognition), digital advertising technology with media content at the shelf based on the Azure AI and IoT platform with data collection and analysis from Sony’s IMX 500 intelligent vision sensor. This also opens new sales opportunities for retailers and creates more customer behavior data to help drive targeted advertising.

The sensor outputs metadata (semantic information belonging to image data) instead of image information, that helps in reducing data traffic and addressing privacy concerns by not collecting personal information. A similar Hanshow solution is already in use at supermarket settings. One major supermarket chain saw a near 50% reduction in out-of-stock time by using similar AI technology.

This solution and three-party collaboration was born out of Microsoft’s Partner Enablement Program which enriches existing tech ecosystems by recruiting qualified partners with experiences, sales and marketing resources to accelerate their time to market through the Microsoft AI & IoT Insider Labs.

Hanshow’s experience in global retail markets, combined with the technological support from Microsoft and Sony “can accelerate co-innovation initiatives to better serve the rapidly changing and diversified retail industry, helping retailers to be more agile and profitable. We are also exploring application of this solution in manufacturing and other industries together with Microsoft and Sony.” said Shiguo Hou, the CEO of Hanshow.

About Hanshow

Hanshow is a global leader in developing and manufacturing electronic shelf labels and digital store solutions. As an innovation leader in the industry, Hanshow is dedicated to offering its global customers a series of world-class customized IoT touchpoints and digital store solutions. Hanshow’s intelligence-enabled platforms and systems deliver customer-centric insights, helping retailers streamline operations and providing various solutions to support optimal pricing strategies to offer consumers a more personalized experience. Hanshow currently serves over 20,000 stores in more than 50 countries. Contact Hanshow: https://www.hanshow.com/Form.html

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye